Clinical Trial Results:
Phase II study to evaluate the clinical potential of 68GaNOTA-Anti-MMR-VHH2 for in vivo imaging of MMR-expressing Macrophages by means of Positron Emission Tomography (PET) in oncological lesions, cardiovascular atherosclerosis, syndrome with abnormal immune activation and sarcoidosis.
|
Summary
|
|
EudraCT number |
2020-002483-31 |
Trial protocol |
BE |
Global completion date |
|
|
Paediatric regulatory details
|
|
Is the trial part of an agreed EMA paediatric investigation plan? |
|
Is the trial in scope of article 45 of Regulation (EC) No 1901/2006? |
|
Is the trial in scope of article 46 of Regulation (EC) No 1901/2006? |
|
|
Results information
|
|
Results version number |
v1(current) |
This version publication date |
24 Jan 2026
|
First version publication date |
24 Jan 2026
|
Other versions |
|
Summary report(s) |
MITRAS - results |
Note: The legislation allows summary attachments to be posted instead of the full dataset for this trial. Refer to Commission Guideline 2012/C 302/03
for further information.